Skip to main content

Advertisement

Figure 2 | BMC Cancer

Figure 2

From: Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid

Figure 2

Kaplan-Meier curves for progression-free survival with different treatments. A. Kaplan-Meier curves for progression-free survival. Notes: Effect of treatment [weekly low-dose zoledronic acid (metronomic arm) versus conventional dose zoledronic acid (conventional arm)] in patients with DFI less than 2 years (N = 17), metronomic arm (N = 7), median = 7.0 months (95% CI, 4.7-9.3 months); conventional arm (N = 10), median = 4.2 months (95% CI, 1.7-6.6 months); P = 0.033. B. Kaplan-Meier curves for progression-free survival. Notes: Effect of treatment [weekly low-dose zoledronic acid (metronomic arm) versus conventional dose zoledronic acid (conventional arm)] in patients with ER negative (N = 18), metronomic arm (N = 7), median = 7.0 months (95% CI, 0-17.3 months); conventional arm (N = 11), median = 2.7 months (95% CI, 0.9-4.6 months); P = 0.021. C. Kaplan-Meier curves for progression-free survival. Notes: Effect of treatment [weekly low-dose zoledronic acid (metronomic arm) versus conventional dose zoledronic acid (conventional arm)] in patients with more than two of pretreated chemotherapy regimens (N = 12), metronomic arm (N = 4), median = 9.8 months (95% CI, 0-22.0 months); conventional arm (N = 8), median = 1.0 months (95% CI, 0.6-1.3 months); P = 0.007. D. Kaplan-Meier curves for progression-free survival. Notes: Effect of treatment [weekly low-dose zoledronic acid (metronomic arm) versus conventional dose zoledronic acid (conventional arm)] in patients with serum CEA baseline levels of greater than 10 μg/L (N = 18), metronomic arm (N = 9), median = 8.1 months (95% CI, 0-22.0 months); conventional arm (N = 9), median = 1.1 months (95% CI, 1.0-1.2 months); P = 0.017. E. Kaplan-Meier curves for progression-free survival. Notes: Effect of treatment [weekly low-dose zoledronic acid (metronomic arm) versus conventional dose zoledronic acid (conventional arm)] in patients with serum CA 15-3 baseline levels of greater than 25 U/mL (N = 38), metronomic arm (N = 17), median = 7.0 months (95% CI, 5.8-8.2 months); conventional arm (N = 21), median = 1.9 months (95% CI, 1.2-2.7 months); P = 0.017. F. Kaplan-Meier curves for progression-free survival. Notes: Effect of treatment [weekly low-dose zoledronic acid (metronomic arm) versus conventional dose zoledronic acid (conventional arm)] in patients with serum NTx baseline levels less than 18 nM BCE (N = 30), metronomic arm (N = 14), median = 5.4 months (95% CI, 3.8-7.0 months); conventional arm (N = 16), median = 1.9 months (95% CI, 0-5.3 months); P = 0.018.

Back to article page